SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines

Lung Cancer

Volumn 85, Issue 1, 2014, Pages 1-6

  Dogan, Irem ^a,b   Kawabata, Shigeru ^c   Bergbower, Emily ^c   Gills, Joell J ^c   Ekmekci, Abdullah ^b   Wilson III, Willie ^a   Rudin, Charles M ^c   Dennis, Phillip A ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GAZI UNIVERSITY   (Turkey)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Akt; EGFR; Erlotinib; H1975; HCC827; Non small cell lung cancer; SOX2

Indexed keywords

DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; ANTINEOPLASTIC AGENT; EGFR PROTEIN, MOUSE; QUINAZOLINE DERIVATIVE; SOX2 PROTEIN, MOUSE; TRANSCRIPTION FACTOR SOX;

ADENOCARCINOMA CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LENTIVIRINAE; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ADENOCARCINOMA; ANIMAL; DRUG RESISTANCE; EXPERIMENTAL NEOPLASM; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MICE, TRANSGENIC; MUTATION; NEOPLASMS, EXPERIMENTAL; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SOXB1 TRANSCRIPTION FACTORS;

EID: 84901620786     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.03.021     Document Type: Article

References (41)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 2:69-90.
2. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
3. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311.
4. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
5. Gazdar A.F. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009, 28(Suppl. 1):S24-S31.
6. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:225-235.
7. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
8. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3. 75ra26.
9. Aoi T., Yae K., Nakagawa M., Ichisaka T., Okita K., Takahashi K., et al. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 2008, 321:699-702.
10. Rousseaux S., Debernardi A., Jacquiau B., Vitte A.L., Vesin A., Nagy-Mignotte H., et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med 2013, 5. 186ra166.
11. Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
12. Nakatsugawa M., Takahashi A., Hirohashi Y., Torigoe T., Inoda S., Murase M., et al. SOX2 is overexpressed in stem-like cells of human lung adenocarcinoma and augments the tumorigenicity. Lab Invest 2011, 91:1796-1804.
13. Chiou S.H., Wang M.L., Chou Y.T., Chen C.J., Hong C.F., Hsieh W.J., et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 2010, 70:10433-10444.
14. Bartholomeusz C., Gonzalez-Angulo A.M. Targeting the PI3K signaling pathway in cancer therapy. Exp Opin Ther Targets 2012, 16:121-130.
15. Canman C.E., Wolff A.C., Chen C.Y., Fornace A.J., Kastan M.B. The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res 1994, 54:5054-5058.
16. Regales L., Balak M.N., Gong Y., Politi K., Sawai A., Le C., et al. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS ONE 2007, 2:e810.
17. Tompkins D.H., Besnard V., Lange A.W., Wert S.E., Keiser A.R., Smith A.N., et al. Sox2 is required for maintenance and differentiation of bronchiolar Clara, ciliated, and goblet cells. PLoS ONE 2009, 4:e8248.
18. West K.A., Castillo S.S., Dennis P.A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 2002, 5:234-248.
19. Jeong C.H., Cho Y.Y., Kim M.O., Kim S.H., Cho E.J., Lee S.Y., et al. Phosphorylation of Sox2 cooperates in reprogramming to pluripotent stem cells. Stem Cells 2010, 28:2141-2150.
20. Curtis S.J., Sinkevicius K.W., Li D., Lau A.N., Roach R.R., Zamponi R., et al. Primary tumor genotype is an important determinant in identification of lung cancer propagating cells. Cell Stem Cell 2010, 7:127-133.
21. Kim C.F., Jackson E.L., Woolfenden A.E., Lawrence S., Babar I., Vogel S., et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005, 121:823-835.
22. Cai Y.R., Zhang H.Q., Qu Y., Mu J., Zhao D., Zhou L.J., et al. Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation. Oncol Rep 2011, 26:877-885.
23. Bass A.J., Watanabe H., Mermel C.H., Yu S., Perner S., Verhaak R.G., et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009, 41:1238-1242.
24. Hussenet T., Dali S., Exinger J., Monga B., Jost B., Dembele D., et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS ONE 2010, 5:e8960.
25. Yuan P., Kadara H., Behrens C., Tang X.M., Woods D., Solis L.M., et al. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS ONE 2010, e9112:5.
26. Rudin C.M., Durinck S., Stawiski E.W., Poirier J.T., Modrusan Z., Shames D.S., et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012, 44:1111-1116.
27. Tian T., Zhang Y., Wang S., Zhou J., Xu S. Sox2 enhances the tumorigenicity and chemoresistance of cancer stem-like cells derived from gastric cancer. J Biomed Res 2012, 26:336-345.
28. Carina V., Zito G., Pizzolanti G., Richiusa P., Criscimanna A., Rodolico V., et al. Multiple pluripotent stem cell markers in human anaplastic thyroid cancer: the putative upstream role of SOX2. Thyroid 2013, 23:829-837.
29. Hagerstrand D., He X.B., Lindh M.B., Hoefs S., Hesselager G., Ostman A., et al. Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile. Neuro-Oncology 2011, 13:1178-1191.
30. Kregel S., Kiriluk K.J., Rosen A.M., Cai Y., Reyes E.E., Otto K.B., et al. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS ONE 2013, 8:e53701.
31. Pirozzi G., Tirino V., Camerlingo R., Franco R., La Rocca A., Liguori E., et al. Epithelial to mesenchymal transition by TGFbeta-1 induction increases stemness characteristics in primary non small cell lung cancer cell line. PLoS ONE 2011, 6:e21548.
32. Hu X., Ghisolfi L., Keates A.C., Zhang J., Xiang S., Lee D.K., et al. Induction of cancer cell stemness by chemotherapy. Cell Cycle 2012, 11:2691-2698.
33. Iida H., Suzuki M., Goitsuka R., Ueno H. Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. Int J Oncol 2012, 40:71-79.
34. Hu Q.K., Zhang L.R., Wen J.H., Wang S.L., Li M.Y., Feng R.P., et al. The Egf receptor-Sox2-Egf receptor feedback loop positively regulates the self-renewal of neural precursor cells. Stem Cells 2010, 28:279-286.
35. Eberl M., Klingler S., Mangelberger D., Loipetzberger A., Damhofer H., Zoidl K., et al. Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells. EMBO Mol Med 2012, 4:218-233.
36. Singh S., Trevino J., Bora-Singhal N., Coppola D., Haura E., Altiok S., et al. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer 2012, 11:73.
37. Chen S., Xu Y., Chen Y., Li X., Mou W., Wang L., et al. SOX2 gene regulates the transcriptional network of oncogenes and affects tumorigenesis of human lung cancer cells. PLoS ONE 2012, 7:e36326.
38. Xiang R., Liao D., Cheng T., Zhou H., Shi Q., Chuang T.H., et al. Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer (vol 104, pg 1410, 2011). Br J Cancer 2011, 104:1931.
39. Xu C., Xie D., Yu S.C., Yang X.J., He L.R., Yang J., et al. beta-catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma. Cancer Res 2013, 73:3181-3189.
40. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
41. Percharde M., Lavial F., Ng J.H., Kumar V., Tomaz R.A., Martin N., et al. Ncoa3 functions as an essential Esrrb coactivator to sustain embryonic stem cell self-renewal and reprogramming. Genes Dev 2012, 26:2286-2298.